Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

Alumis (ALMS) shares climbed nearly 150% on Tuesday after the autoimmune disease drug developer said its lead candidate, ...

Alumis, a clinical-stage biopharmaceutical company, has announced two phase 3 trials of its TYK2 inhibitor envudeucitinib met their co-primary endpoints in adults with moderate to severe plaque ...

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong ...

Biotech stock Alumis catapulted on Tuesday after the company unveiled promising results that could help it compete against ...

Alumis said on Tuesday its experimental drug met the main goal of improving symptoms of a common skin disease in two late-stage studies, powering its shares to a record high and more than doubling ...

Shares of Alumis surged after the company said both of its phase three trials of its envudeucitinib drug for moderate-to-severe plaque psoriasis met all primary and secondary endpoints. The stock more ...

Takeda Pharmaceutical Co. announced that its oral psoriasis drug zasocitinib proved safe and effective in late-stage trials, marking a milestone in its effort to treat the incurable skin condition and ...

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Alumis (ALMS) stock is soaring after the company announced positive trial results for its plaque psoriasis drug ...

Investing.com -- Alumis Inc. (NASDAQ:ALMS) stock surged 60% Tuesday after the company reported positive Phase 3 trial results for its psoriasis drug envudeucitinib, showing superior skin clearance ...

Cosentyx (secukinumab) is a brand-name drug that’s prescribed for certain conditions, including plaque psoriasis and psoriatic arthritis. This article covers topics such as side effects, dosage, and ...